INDEPENDENT ASSESSMENT
TogetherMade, PBC is a 2025 Delaware public-benefit corporation building clinical decision-support infrastructure for physicians and other providers working in settings where conventional medical guidance may not match the resources actually available. Its September 15, 2026 Form D reports an $850,000 Rule 506(b) offering, $450,000 sold to five investors, $400,000 remaining, a September 1 first sale and a $5,000 minimum investment. The issuer selected Other Health Care, declined to disclose revenue, reported no broker or finder compensation and stated that the offering is not expected to last more than one year. Katheryn "Kat" Grider is listed as President, Director and Executive Officer; Lacey LaGrone is listed as Director, Secretary and Executive Officer. Grider signed the filing as President. The financing is therefore an early-stage operating-company raise rather than a pooled investment vehicle, and roughly 52.9% of the stated offering had been sold at filing. The SEC filing does not disclose company valuation, ownership percentage or the exact security terms, so the $450,000 raised should not be converted into an implied valuation without the actual financing documents.
THE CORRECT TOGETHERMADE IS A HEALTHCARE AI COMPANY, NOT THE CRAFT BUSINESS WITH THE SIMILAR DOMAIN
Entity resolution is unusually important here because an older and unrelated company called TogetherMade LLC operates togethermade.com and historically sold DIY leather and woodworking kits. That business identifies Jeb and Kellie Haber as founders, dates back to 2018 and has federal trademarks covering craft kits. It has no demonstrated relationship to the healthcare issuer. TogetherMade, PBC instead operates at together-made.com, identifies itself as a public-health and clinical decision-support company, names Kat Grider and Lacey LaGrone on its leadership team and uses branding focused on clinician decision making rather than consumer crafts. FilingDossier should therefore never populate the healthcare issuer's WEBSITE field with togethermade.com merely because search engines rank that older domain highly. The hyphenated domain is the relevant operating site for the SEC issuer.
THE PRODUCT IS RESOURCE-ADAPTIVE CLINICAL DECISION SUPPORT
TogetherMADE's core thesis is more specific than generic "AI for healthcare." The company argues that many clinical guidelines assume access to specialists, medications, diagnostics or equipment that may not exist in community hospitals, rural clinics or lower-resource health systems. Its platform is designed to adapt guidance to what a clinician actually has available at the moment of care. The company describes three product layers: evidence-informed resource-adaptive decision trees, a moderated Community of Practice where clinicians can exchange knowledge, and a bedside-ready chat-enabled application. TogetherMADE says the platform combines clinician-in-the-loop AI, machine learning and peer-to-peer networks, while a proprietary decision graph underpins the decision-support logic. The company currently labels that technology patent pending.
That product design materially differentiates TogetherMADE from a simple medical chatbot. The intended value is not merely answering a medical question from a large language model; it is narrowing a decision pathway using local constraints such as available medicines, tools, trained personnel and referral capacity. In theory, that can be especially valuable in trauma and emergency care, where a textbook recommendation may be impossible to execute immediately. It also creates a much harder validation problem: the system must not only retrieve correct medical knowledge but correctly understand which local resources are available, how recommendations change when those resources are missing and when escalation to a human expert is required.
THE COMPANY GREW OUT OF TRAUMA-CARE AND IMPLEMENTATION-SCIENCE WORK
Lacey LaGrone provides a particularly strong research and clinical bridge. TogetherMADE identifies her as a trauma surgeon with graduate training and approximately eight years of dissemination and implementation-science research. Independent academic literature confirms LaGrone's involvement in work focused on how point-of-care medical information systems can be implemented in trauma and general-surgery practice in resource-constrained environments. A 2023 implementation-science paper lists Lacey Nicole LaGrone among the researchers studying adoption of point-of-care medical information systems in a middle-income country. That makes the company's product thesis more credible as an extension of prior clinical research rather than a health-AI concept created only for fundraising.
The development path also appears in the 2025 Design for Implementation conference proceedings. Published proceedings list LaGrone and Kat Grider together on a session examining new approaches to clinical-guidance generation, while Grider separately presented a "Purpose-to-Practice" framework focused on designing for scalability and sustainability. This is valuable independent evidence because it predates the September 2026 financing and shows both founders already working together on the exact problem TogetherMADE later commercialized: how evidence becomes usable guidance in real clinical environments.
KAT GRIDER BRINGS A VERY DIFFERENT OPERATING BACKGROUND
Kat Grider's experience complements LaGrone's clinical background rather than duplicating it. TogetherMADE identifies Grider as CEO and describes more than 25 years of experience in digital marketing, advertising, customer experience and transformational digital builds. The company says her prior work included digital experience and media initiatives around Xbox, Surface, Windows, ADT and Gates Foundation-related campaigns. Her public professional profile similarly describes a long career building digital platforms and leading large-scale digital experience work.
That division of labor is important. TogetherMADE is attempting to build not only a medically credible tool but a product clinicians will actually adopt in stressful workflows. A trauma surgeon may understand what guidance must contain, while a digital-product executive may be better positioned to design onboarding, information architecture, usability and distribution. Public records do not yet show how many full-time engineers, data scientists or clinical-safety personnel the company employs, so investors should not assume that the two founders alone represent the complete operating team.
THE EARLY VALIDATION STORY IS COMMUNITY-BASED RATHER THAN REVENUE-BASED
TogetherMADE currently emphasizes clinical participation and partnerships more heavily than commercial revenue. Its public materials say the platform has been informed by clinicians in more than 15 countries, while a recent company update says it has been shaped by conversations with more than 100 clinicians across nine countries. The company also says its Community of Practice includes members of the Rural Surgeons of India and that it is pursuing research partnerships with institutions including Boston Children's Hospital. These claims indicate meaningful clinician engagement, but they should not be presented as equivalent to paying customers, active enterprise contracts or validated health outcomes.
The distinction matters because the Form D declines to disclose revenue rather than checking No Revenues. We therefore cannot conclude that the company has no revenue, but neither can public materials establish material commercial traction. Investor diligence should separate four categories carefully: clinicians who provided product feedback, research collaborators, institutional partners and paying customers. A hospital or clinician participating in a pilot or research discussion is not automatically a commercial customer.
PARTNER CLAIMS ARE SIGNIFICANT BUT NEED PRECISE LANGUAGE
TogetherMADE's website lists organizations including the Society of Trauma Nurses, University of Alabama, Gates Foundation, Boston Consulting Group, MediTech Foundation, Tactuum and the Coalition for National Trauma Research under its Partners section. The company says it has received input and direction from members of listed organizations and funding or in-kind support from several of them. This wording matters: it does not mean every displayed organization is an equity investor, customer or formal institutional endorser.
Recent company communications additionally refer to work with leaders at WHO collaborating centers and support from the Gates Foundation. Again, those statements should remain attributed to TogetherMADE unless a separate grant database, contract or institutional announcement independently confirms the exact funding amount and legal relationship. For FilingDossier, the strongest approach is to state that the company publicly identifies these organizations as contributors, partners, supporters or sources of input while avoiding stronger claims such as "WHO-backed company" or "Gates-funded startup" unless the underlying award documents are found.
THE 2026 ROUND USES A NONSTANDARD SECURITY STRUCTURE
The Form D does not check ordinary equity or debt. Instead, it checks "Option, Warrant or Other Right to Acquire Another Security" and also "Other." That is important because investors may be purchasing a convertible or contractual instrument rather than immediately receiving common or preferred shares. The filing does not provide the descriptive text needed to determine the exact security mechanics. It could involve warrants, SAFEs, convertible rights or another hybrid security, but the public filing does not justify choosing among them.
The $450,000 sold to five investors implies an average of $90,000 per investor if subscriptions were equal, though actual amounts may differ considerably. The $5,000 minimum is therefore not representative of the average reported capital deployed so far. The issuer also reports $0 commissions, $0 finder fees and an estimated $0 of offering proceeds earmarked for payments to Grider or LaGrone under Form D Item 16. That is useful evidence that the filing does not disclose large insider-payment allocations of the kind seen in some other E-list offerings.
THE PUBLIC-BENEFIT CORPORATION STRUCTURE FITS THE MISSION
TogetherMade is organized as a Delaware PBC, or public-benefit corporation. That structure allows a corporation to state a public benefit alongside shareholder economic interests and is increasingly used by companies with healthcare, environmental or social missions. In this case, the structure aligns naturally with TogetherMADE's stated goal of improving access to clinically relevant knowledge across under-resourced settings.
The PBC label should not be interpreted as nonprofit status. TogetherMade remains a for-profit corporation raising private capital. Investors therefore still need to understand how management balances mission objectives with commercialization, pricing, hospital procurement and investor returns. If the company intends to make the platform affordable in lower-resource settings, the economic model may depend on institutional licensing, philanthropic support, cross-subsidization or partnerships rather than direct clinician subscriptions alone.
AI SAFETY AND CLINICAL GOVERNANCE ARE THE CENTRAL INVESTMENT RISKS
TogetherMADE operates in one of the highest-consequence AI categories. Clinical decision support can influence diagnosis, treatment, transfer decisions and emergency management. The company emphasizes clinician-in-the-loop governance and community validation specifically because generative AI can hallucinate or overstate certainty. That architecture is directionally important, but investors need much more detail: who can approve guidance, how sources are weighted, how frequently content is updated, how disagreements among clinicians are resolved, how AI-generated recommendations are audited and whether every output remains traceable to evidence.
Regulatory classification is another major diligence area. Depending on exactly how the software functions and how clinicians rely on it, portions of the platform could implicate FDA clinical decision-support or software-as-a-medical-device frameworks. The precise legal analysis depends on whether clinicians can independently review the basis for recommendations, whether the software makes patient-specific treatment recommendations and how outputs are presented. Public materials do not establish the company's final regulatory classification, so investors should request the regulatory strategy rather than assuming the platform is either FDA-regulated or exempt.
HIPAA and information security also matter. TogetherMADE advertises a HIPAA-compliant peer community, and a bedside application could potentially encounter protected health information. Investors should understand whether patient-level data ever enters the platform, how identifiers are removed, where data are hosted, what model providers receive information and whether the company has completed independent security assessments. A clinical tool can have strong AI logic and still fail commercially if hospital security and compliance teams do not approve deployment.
THE BUSINESS MODEL STILL NEEDS TO BE PROVEN
The website explains the clinical mission much more clearly than the monetization model. Potential revenue paths could include hospital licenses, health-system subscriptions, professional-society licensing, research partnerships, grants or enterprise contracts. TogetherMADE also says royalties can flow back to hospitals, societies and researchers whose content and insights power the platform, suggesting some form of knowledge-contributor economics. That could become an important differentiator if it encourages high-quality institutional content, but it also introduces contractual complexity around intellectual property, revenue sharing and content governance.
Investors should request pricing, pilot conversion rates, sales-cycle data, annual contract value, deployment cost and gross-margin assumptions. Hospital software procurement can be slow even when clinicians strongly support a product. Integration with EHR systems, cybersecurity reviews, legal approvals, clinical governance committees and budget cycles can all delay revenue. The company's community-first approach may create trust and product insight, but commercial adoption must ultimately be measured separately.
RISK AND DILIGENCE QUESTIONS
The strongest evidence supports TogetherMADE's identity, leadership, mission and research foundation. SEC records verify Kat Grider and Lacey LaGrone as directors and executive officers. The official website shows a functioning beta product and clearly describes its decision-support architecture. Academic publications independently confirm LaGrone's implementation-science work and show Grider and LaGrone collaborating on clinical-guidance design before this fundraising round. What remains much less visible is the commercial layer: revenue, paid hospitals, annual recurring revenue, pilot-to-contract conversion, regulatory status and independently measured clinical outcomes.
Investors should therefore request the actual financing instrument, capitalization table, IP and patent schedule, product validation studies, clinical-safety framework, FDA/regulatory analysis, security architecture, HIPAA documentation, pilot agreements, customer pipeline and financial model. They should also verify the precise legal relationship with each organization displayed as a partner or supporter and distinguish grants, research collaborations, in-kind contributions and commercial contracts.
FINAL ASSESSMENT
TogetherMade, PBC has one of the more differentiated operating stories in this E-list. The September 2026 Form D confirms an $850,000 Rule 506(b) offering with $450,000 sold to five investors, Kat Grider as President and Director, Lacey LaGrone as Director and Secretary, and an Other Health Care classification. The correct operating company is the healthcare platform at together-made.com, not the unrelated TogetherMade craft-kit company at togethermade.com. TogetherMADE's public product combines resource-adaptive clinical decision trees, clinician-in-the-loop AI, a moderated professional community and a bedside application designed especially for settings where conventional guidelines assume resources that are not actually available.
The company also has more substantive pre-financing research context than many early-stage health-AI startups. LaGrone has published implementation-science work in resource-constrained clinical settings, and 2025 conference proceedings document LaGrone and Grider working together on clinical-guidance generation before the SEC round. The largest unresolved questions are now commercial and regulatory: exact financing terms, revenue, paying institutions, AI validation, clinical safety, HIPAA architecture and potential FDA treatment. The $450,000 figure is reported securities sold, not company valuation or evidence of clinical effectiveness. Form D confirms the private financing; it does not constitute SEC or medical-regulatory approval of the platform.